)
Visual
test
Black Diamond Therapeutics
Black Diamond Therapeutics (BDTX) investor relations material
Black Diamond Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary16 Mar, 2026
Executive summary
Advanced silevertinib clinical program with Phase 2 NSCLC trial showing promising efficacy and safety as of November 2025.
Preparing to initiate a randomized Phase 2 trial in EGFR-altered GBM in Q2 2026.
Focused pipeline after outlicensing BDTX-4933 and restructuring for operational efficiency.
Financial highlights
Ended 2025 with $128.7 million in cash, cash equivalents, and investments, up from $98.6 million at end of 2024.
Net income for 2025 was $22.4 million, compared to a net loss of $69.7 million in 2024.
License revenue of $70 million recognized in 2025.
R&D expenses for 2025 were $33.6 million, down from $51.3 million in 2024.
G&A expenses for 2025 were $16.6 million, down from $27.5 million in 2024.
Outlook and guidance
Cash position expected to fund operations into the second half of 2028.
Updated clinical data for silevertinib in NSCLC and GBM expected in Q2 2026.
Criteria for selecting a silevertinib partner
Rationale for the randomized Phase 2 GBM trial
Impact of CNS ORR on frontline NSCLC positioning
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Black Diamond Therapeutics
- Silevertinib demonstrates robust efficacy in NSCLC and is advancing to pivotal GBM trials.BDTX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - BDTX-1535 achieved 42% ORR and durable responses in resistant EGFRm NSCLC at 200 mg.BDTXStudy Update20 Jan 2026
- BDTX-1535 shows strong efficacy and safety in NSCLC, with pivotal data expected in 2025.BDTXStifel 2024 Healthcare Conference13 Jan 2026
- Phase 2 EGFR inhibitor shows strong efficacy and safety; key 2025 data and regulatory updates ahead.BDTXPiper Sandler 36th Annual Healthcare Conference11 Jan 2026
- BDTX-1535 shows promise in NSCLC and GBM, with pivotal data and regulatory milestones ahead.BDTX24th Annual Needham Virtual Healthcare Conference27 Dec 2025
- Lead oral therapy 1535 targets broad NCMs in NSCLC, with pivotal data and FDA update in Q4 2024.BDTXStifel 2025 Virtual Targeted Oncology Forum23 Dec 2025
- Shelf registration allows up to $500M in offerings, with $150M at-the-market via Jefferies.BDTXRegistration Filing16 Dec 2025
- Silevertinib’s Phase II data show high response and CNS activity in lung cancer, with pivotal trials ahead.BDTXPiper Sandler 37th Annual Healthcare Conference7 Dec 2025
- Silevertinib shows strong efficacy and CNS activity in NSCLC and advances to phase II GBM trial.BDTXStudy Update3 Dec 2025
Next Black Diamond Therapeutics earnings date
Q1 20268 May, 2026
Black Diamond Therapeutics
Next Black Diamond Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage